Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RG 6596

Next Previous
Drug Profile

RG 6596

Alternative Names: RG-6596; ZN-1041; ZN-A-1041

Latest Information Update: 14 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Zanrong Pharmaceutical Technology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HER2 positive breast cancer; Solid tumours

Most Recent Events

  • 27 Jun 2025 Genentech initiates enrolment in a phase I trial (In volunteers) in United Kingdom (NCT07051993)
  • 10 Dec 2024 Updated efficacy and adverse events data from a phase I trial in HER2-positive breast cancer presented at the 47th Annual San Antonio Breast Cancer Symposium (SABCS-2024)
  • 14 Feb 2024 RG 6596 is still in phase-I trials for HER2-positive-breast-cancer and Solid tumours in China and USA (Roche pipeline, February 2024) (NCT04487236), (NCT05593094)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top